Drug General Information
Drug ID	D0XV4Z
Former ID	DNCL002821
Drug Name	TD-4208
Indication	Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47]		Phase 3	[525280]
Company	Theravance
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Muscarinic receptor	Target Info	Antagonist	[532360]
KEGG Pathway	Calcium signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	PI3K-Akt signaling pathway
	Cholinergic synapse
	Regulation of actin cytoskeleton
PathWhiz Pathway	Muscle/Heart Contraction
Reactome	Muscarinic acetylcholine receptors
	Acetylcholine regulates insulin secretion
	G alpha (q) signalling events
WikiPathways	Monoamine GPCRs
	Calcium Regulation in the Cardiac Cell
	Regulation of Actin Cytoskeleton
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Secretion of Hydrochloric Acid in Parietal Cells
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 525280	ClinicalTrials.gov (NCT02512510) Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD).
Ref 532360	In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013 Aug;346(2):241-50.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.